Hydroxychloroquine hitting the headlines-retinal considerations

Susan M Downes^{1

2}, Bart P Leroy^{3

4}, Srilakshmi M Sharma⁵, Sobha Sivaprasad^{6

7}, Hélène Dollfus^{8

9}

Affiliations

¹ Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK. susan.downes@eye.ox.ac.uk.
² Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. susan.downes@eye.ox.ac.uk.
³ Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium.
⁴ Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
⁵ Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
⁶ Moorfields Eye Hospital, London, UK.
⁷ Institute of Ophthalmology, London, UK.
⁸ University Hospitals of Strasbourg, Strasbourg, France.
⁹ University of Strasbourg, Strasbourg, France.

Editorial

Susan M Downes et al. Eye (Lond). 2020 Jul.

. 2020 Jul;34(7):1158-1160.

doi: 10.1038/s41433-020-0934-9. Epub 2020 May 19.

Susan M Downes^{1

2}, Bart P Leroy^{3

4}, Srilakshmi M Sharma⁵, Sobha Sivaprasad^{6

7}, Hélène Dollfus^{8

9}

¹ Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK. susan.downes@eye.ox.ac.uk.
² Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. susan.downes@eye.ox.ac.uk.
³ Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium.
⁴ Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
⁵ Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
⁶ Moorfields Eye Hospital, London, UK.
⁷ Institute of Ophthalmology, London, UK.
⁸ University Hospitals of Strasbourg, Strasbourg, France.
⁹ University of Strasbourg, Strasbourg, France.

No abstract available

Conflict of interest statement

The authors declare that they have no conflict of interest

1. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye. 2017. 10.1038/eye.2016.298. - PMC - PubMed
1. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology. 2016;123:1386–94. doi: 10.1016/j.ophtha.2016.01.058. - DOI - PubMed
1. Gautret P Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. 10.1016/j.ijantimicag.2020.105949. - PMC - PubMed
1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020. 10.5582/bst.2020.01047. - PubMed
1. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ. 2020;49. 10.3785/j.issn.1008-9292.2020.03.03. - PubMed